Gastritis cystica profunda is associated with aberrant p53 and Epstein-Barr virus in gastric cancer: A clinicopathological, immunohistochemical and in situ hybridization study.
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ analysis
Epstein-Barr Virus Infections
/ complications
Female
Gastric Mucosa
/ pathology
Gastritis
/ pathology
Gastrointestinal Neoplasms
/ pathology
Herpesvirus 4, Human
/ isolation & purification
Humans
Immunohistochemistry
In Situ Hybridization
Male
Middle Aged
Stomach Neoplasms
/ pathology
Tumor Suppressor Protein p53
/ analysis
Epstein-Barr virus
PD-L1
gastric cancer
gastritis cystica profunda
p53
Journal
Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
03
08
2020
accepted:
02
10
2020
pubmed:
22
10
2020
medline:
15
10
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
Gastritis cystica profunda (GCP) is a lesion characterized by cystic gastric glands within the submucosa. Some studies have reported that GCP is a precancerous lesion. Here, we investigated the association between GCP and gastric cancer. Gastric cancer specimens were taken from 1432 patients undergoing surgery or endoscopic submucosal resection and were classified as GCP or non-GCP. The clinicopathological features, immunohistochemistry and in situ hybridization expression of p53, Ki-67, KCNE2, Epstein-Barr virus (EBV) and programmed death ligand 1 (PD-L1) were compared between the two groups, as well as between GCPs and normal pyloric glands. One hundred and eighty patients (12.6%) had GCPs. In the GCP group, no cancerous lesions were found within the GCPs, but 13% were linked to GCPs and 60.2% were located above or near GCPs. Aberrant p53 expression, EBV-positive cancer cells and PD-L1 scores were significantly higher in the GCP group. The p53 score and Ki-67 labelling index were significantly higher and the KCNE2 score was significantly lower in GCPs than in pyloric glands. Although we suggest GCP is paracancerous, GCP has high proliferation activity and gastric cancer with GCP is associated with aberrant p53 and EBV. GCP is associated with aberrant p53 expression and EBV.
Substances chimiques
B7-H1 Antigen
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-50Informations de copyright
© 2020 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Références
Littler ER, Gleibermann E. Gastritis cystic polyposa (gastric mucosal prolapse at gastroenterostomy site, with cystic and infiltrative epithelial hyperplasia). Cancer 1972; 29: 205-9.
Franzin G, Novelli P. Gastritis cystica profunda. Histopathology 1981; 5: 535-47.
Moon SY, Kim KO, Park SH et al. Gastritis cystica profunda accompanied by multiple early gastric cancers. Korean J Gastroenterol 2010; 55: 325-30.
Laratta JL, Buhtoiarova TN, Sparber LS, Ronald S, Chamberlain RS. Gastritis cystica profunda: A rare gastric tumor masquerading as a malignancy. Surg Sci 2012; 3: 158-64.
Ogasawara N, Noda H, Kondo Y et al. A case of early gastric cancer arising from gastritis cystica profunda treated by endoscopic submucosal dissection. Case Rep Gastroenterol 2014; 8: 270-75.
Iwanaga T, Koyama H, Takahashi Y, Taniguchi H, Wada A. Diffuse submucosal cysts and carcinoma of the stomach. Cancer 1975; 36: 606-14.
Béchade D, Desramé J, Algayres JP. Gastritis cystica profunda in a patient with no history of gastric surgery. Endoscopy 2007; 39: 80-81.
Namikawa T, Ishida N, Yokota K et al. Early gastric cancer with multiple submucosal heterotopic gastric gland: A case report. Mol Clin Oncol 2019; 10: 583-86
Mitomi H, Iwabuchi K, Amemiya A, Kaneda G, Adachi K, Asao T. Immunohistochemical analysis of a case of gastritis cystica profunda associated with carcinoma development. Scand J Gastroenterol 1998; 33: 1226-9.
Ochiai M, Matsubara T, Zhi LZ et al. Gastritis cystica polyposa associated with a gastric stump carcinoma, with special reference to cell kinetics and p53 gene aberrations. Gastric Cancer 2000; 3: 165-70.
Roepke TK, Purtell K, King EC, La Perle KM, Lerner DJ, Abbott GW. Targeted deletion of Kcne2 causes gastritis cystica profunda and gastric neoplasia. PLoS One 2010; 5: e11451.
Kuwahara N, Kitazawa R, Fujiishi K, Nagai Y, Haraguchi R, Kitazawa S. Gastric adenocarcinoma arising in gastritis cystica profunda presenting with selective loss of KCNE2 expression. World J Gastroenterol 2013; 19: 1314-7.
Choi MG, Jeong JY, Kim KM et al. Clinical significance of gastritis cystica profunda and its association with Epstein-Barr virus in gastric cancer. Cancer 2012; 118: 5227-33.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-9.
Ma C, Patel K, Singhi AD et al. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability. Am J Surg Pathol 2016; 40: 1496-506.
Saito R, Abe H, Kunita A, Yamashita H, Seto Y, Fukayama M. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: The prognostic implications. Mod Pathol 2017; 30: 427-39.
Nakayama A, Abe H, Kunita A et al. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma. PLoS One 2019; 14: e0211358.
Carneiro F, Fukayama M, Grabsch HI, Yasui W Gastric adenocarcinoma. In: Who Classification of Tumors Editorial Board, eds. World Health Organization Classification of Tumors. Digestive System Tumors, 5th ed. Lyon: IARC Press, 2019; 85-95.
Laurén P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64: 31-49.
Kamata Y, Kurotaki H, Onodera T, Nishida N. An unusual heterotopia of pyloric glands of the stomach with inverted downgrowth. Acta Pathol Jpn 1993; 43: 192-7.
Matsushita M, Mori S, Tahashi Y, Uchida K, Nishio A, Okazaki K. Gastritis cystica polyposa in the operated stomach and heterotopic submucosal cysts in the unoperated stomach. Gastrointest Endosc 2010; 71: 1100-02.
Tominaga K, Nimura S, Takahashi K, Maetani I. Gastrointestinal bleeding caused by gastritis cystica polyposa. BMJ Case Rep 2011; 2011: bcr082011, 20114617-bcr0820114617.
Yanglin P, Lina Z, Zhiguo L et al. KCNE2, a down-regulated gene identified by in silico analysis, suppressed proliferation of gastric cancer cells. Cancer Lett 2007; 8: 129-38.
Ando K, Oki E, Saeki H et al. Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. Cancer 2015; 4: 75-83.
Setia N, Agoston AT, Han HS et al. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol 2016; 29: 772-84.
Ahn S, Lee SJ, Kim Y et al. High-throughput protein and mRNA expression-based classification of gastric cancers can identify clinically distinct subtypes, concordant with recent molecular classifications. Am J Surg Pathol 2017; 41: 106-15.
Yamagiwa H, Matsuzaki O, Ishihara A, Yoshimura H. Heterotopic gastric glands in the submucosa of the stomach. Acta Pathol Jpn 1979; 29: 347-50.
Kim DH, Kim KM, Oh SJ et al. Early gastric cancer arising from heterotopic gastric mucosa in the gastric submucosa. J Korean Surg Soc 2011; 80: 6-11.
Imamura T, Komatsu S, Chikawa, D et al. Gastric carcinoma originating from the heterotopic submucosal gastric gland treated by laparoscopy and endoscopy cooperative surgery. World J Gastrointest Oncol 2015; 7: 118-22.
Kim L, Kim JM, Hur YS et al. Extended gastritis cystica profunda associated with Epstein-Barr virus-positive dysplasia and carcinoma with lymphoid stroma. Pathol Int 2012; 62: 351-55.
Kaizaki Y, Hosokawa O, Sakurai S, Fukayama M. Epstein-Barr virus-associated gastric carcinoma in the remnant stomach: De novo and metachronous gastric remnant carcinoma. J Gastroenterol 2005; 40: 570-77.
Ryan JL, Shen YJ, Morgan DR et al. Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig Dis Sci 2012; 57: 1887-98.
Gudkov AV, Komarova EA. P53 and the carcinogenicity of chronic inflammation. Cold Spring Harb Perspect Med 2016; 6: a026161.
Kodama M, Murakami K, Okimoto T, Shin YW, Park IS, Choi SJ. Expression of mutant type-p53 products in H pylori-associated chronic gastritis. World J Gastroenterol 2007; 13: 1541-6.
Li N, Xie C, Lu NH. p53, a potential predictor of Helicobacter pylori infection-associated gastric carcinogenesis? Oncotarget 2016; 7: 66276-86.
Pandey S, Jha HC, Shukla SK, Shirley MK, Robertson ES. Epigenetic regulation of tumor suppressors by Helicobacter pylori enhances EBV-induced proliferation of gastric epithelial cells. mBio 2018; 9: e00649-718.
Machicado J, Jelinek K, Shroff J et al. Gastritis cystica profunda: Endoscopic ultrasound findings and review of the literature. Endosc Ultrasound 2014; 3: 131-4.
Ribeiro J, Malta M, Galaghar A et al. P53 deregulation in Epstein-Barr virus-associated gastric cancer. Cancer Lett 2017; 404: 37-43.
Zheng X, Wang J, Wei L et al. Epstein-Barr virus microRNA miR-BART5-3p inhibits p53 expression. J Virol 2018; 92: e01022.
Liu Z, Wang Y, Luo X, Wang Y, Zhang L, Wang T. Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis. Int J Clin Exp Pathol 2017; 10: 11754-9.